Pharmacokinetics	B:C0031327
of	O
Repeated	O
Melatonin	O
Drug	O
Administrations	I:C3469597
Prior	O
to	O
and	O
After	O
Surgery	O
Recent	O
clinical	O
studies	I:C0008972
have	O
documented	O
the	O
analgesic	O
,	O
anti-inflammatory	O
,	O
antioxidative	O
and	O
anxiolytic	O
effects	I:C3179404
of	O
exogenous	O
melatonin	O
.	O

Pharmacokinetics	O
of	O
Repeated	O
Melatonin	B:C0025219
Drug	O
Administrations	I:C3469597
Prior	O
to	O
and	O
After	O
Surgery	O
Recent	O
clinical	O
studies	I:C0008972
have	O
documented	O
the	O
analgesic	O
,	O
anti-inflammatory	O
,	O
antioxidative	O
and	O
anxiolytic	O
effects	I:C3179404
of	O
exogenous	O
melatonin	O
.	O

Pharmacokinetics	O
of	O
Repeated	O
Melatonin	O
Drug	B:C3469597
Administrations	I:C3469597
Prior	O
to	O
and	O
After	O
Surgery	O
Recent	O
clinical	O
studies	I:C0008972
have	O
documented	O
the	O
analgesic	O
,	O
anti-inflammatory	O
,	O
antioxidative	O
and	O
anxiolytic	O
effects	I:C3179404
of	O
exogenous	O
melatonin	O
.	O

Pharmacokinetics	O
of	O
Repeated	O
Melatonin	O
Drug	O
Administrations	I:C3469597
Prior	O
to	O
and	O
After	O
Surgery	O
Recent	O
clinical	B:C0008972
studies	I:C0008972
have	O
documented	O
the	O
analgesic	O
,	O
anti-inflammatory	O
,	O
antioxidative	O
and	O
anxiolytic	O
effects	I:C3179404
of	O
exogenous	O
melatonin	O
.	O

Pharmacokinetics	O
of	O
Repeated	O
Melatonin	O
Drug	O
Administrations	I:C3469597
Prior	O
to	O
and	O
After	O
Surgery	O
Recent	O
clinical	O
studies	I:C0008972
have	O
documented	B:C1301725
the	O
analgesic	O
,	O
anti-inflammatory	O
,	O
antioxidative	O
and	O
anxiolytic	O
effects	I:C3179404
of	O
exogenous	O
melatonin	O
.	O

Pharmacokinetics	O
of	O
Repeated	O
Melatonin	O
Drug	O
Administrations	I:C3469597
Prior	O
to	O
and	O
After	O
Surgery	O
Recent	O
clinical	O
studies	I:C0008972
have	O
documented	O
the	O
analgesic	B:C0948482
,	O
anti-inflammatory	O
,	O
antioxidative	O
and	O
anxiolytic	O
effects	I:C3179404
of	O
exogenous	O
melatonin	O
.	O

Pharmacokinetics	O
of	O
Repeated	O
Melatonin	O
Drug	O
Administrations	I:C3469597
Prior	O
to	O
and	O
After	O
Surgery	O
Recent	O
clinical	O
studies	I:C0008972
have	O
documented	O
the	O
analgesic	O
,	O
anti-inflammatory	O
,	O
antioxidative	B:C3179302
and	O
anxiolytic	O
effects	I:C3179404
of	O
exogenous	O
melatonin	O
.	O

Pharmacokinetics	O
of	O
Repeated	O
Melatonin	O
Drug	O
Administrations	I:C3469597
Prior	O
to	O
and	O
After	O
Surgery	O
Recent	O
clinical	O
studies	I:C0008972
have	O
documented	O
the	O
analgesic	O
,	O
anti-inflammatory	O
,	O
antioxidative	O
and	O
anxiolytic	B:C3179404
effects	I:C3179404
of	O
exogenous	O
melatonin	O
.	O

Pharmacokinetics	O
of	O
Repeated	O
Melatonin	O
Drug	O
Administrations	I:C3469597
Prior	O
to	O
and	O
After	O
Surgery	O
Recent	O
clinical	O
studies	I:C0008972
have	O
documented	O
the	O
analgesic	O
,	O
anti-inflammatory	O
,	O
antioxidative	O
and	O
anxiolytic	O
effects	I:C3179404
of	O
exogenous	O
melatonin	B:C0025219
.	O

The	O
pharmacokinetic	B:C0031327
properties	I:C0031327
of	O
melatonin	O
have	O
primarily	O
been	O
investigated	O
in	O
experimental	O
studies	I:C0681814
.	O

The	O
pharmacokinetic	O
properties	I:C0031327
of	O
melatonin	B:C0025219
have	O
primarily	O
been	O
investigated	O
in	O
experimental	O
studies	I:C0681814
.	O

The	O
pharmacokinetic	O
properties	I:C0031327
of	O
melatonin	O
have	O
primarily	O
been	O
investigated	O
in	O
experimental	B:C0681814
studies	I:C0681814
.	O

The	O
aim	O
of	O
this	O
study	B:C2603343
was	O
to	O
estimate	O
the	O
pharmacokinetics	O
of	O
melatonin	O
in	O
patients	O
undergoing	O
surgery	O
and	O
general	O
anesthesia	I:C0002915
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
pharmacokinetics	B:C0031327
of	O
melatonin	O
in	O
patients	O
undergoing	O
surgery	O
and	O
general	O
anesthesia	I:C0002915
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
pharmacokinetics	O
of	O
melatonin	B:C0025219
in	O
patients	O
undergoing	O
surgery	O
and	O
general	O
anesthesia	I:C0002915
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
pharmacokinetics	O
of	O
melatonin	O
in	O
patients	O
undergoing	O
surgery	B:C0543467
and	O
general	O
anesthesia	I:C0002915
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
estimate	O
the	O
pharmacokinetics	O
of	O
melatonin	O
in	O
patients	O
undergoing	O
surgery	O
and	O
general	B:C0002915
anesthesia	I:C0002915
.	O

The	O
study	O
was	O
designed	O
as	O
a	O
prospective	B:C1709709
,	I:C1709709
two	I:C1709709
-	I:C1709709
phase	I:C1709709
cohort	I:C1709709
study	I:C1709709
.	O

Patients	O
were	O
candidates	O
for	O
subpectoral	B:C0030747
breast	O
augmentation	I:C0191925
surgery	I:C0191925
,	O
and	O
surgical	O
procedures	I:C0543467
were	O
performed	O
by	O
a	O
single	O
surgeon	O
.	O

Patients	O
were	O
candidates	O
for	O
subpectoral	O
breast	B:C0191925
augmentation	I:C0191925
surgery	I:C0191925
,	O
and	O
surgical	O
procedures	I:C0543467
were	O
performed	O
by	O
a	O
single	O
surgeon	O
.	O

Patients	O
were	O
candidates	O
for	O
subpectoral	O
breast	O
augmentation	I:C0191925
surgery	I:C0191925
,	O
and	O
surgical	B:C0543467
procedures	I:C0543467
were	O
performed	O
by	O
a	O
single	O
surgeon	O
.	O

Patients	O
were	O
candidates	O
for	O
subpectoral	O
breast	O
augmentation	I:C0191925
surgery	I:C0191925
,	O
and	O
surgical	O
procedures	I:C0543467
were	O
performed	O
by	O
a	O
single	O
surgeon	B:C0582175
.	O

The	O
perioperative	O
treatment	B:C0040808
protocol	I:C0040808
was	O
standardized	O
between	O
patients	O
.	O

During	O
the	O
study	B:C2603343
,	O
each	O
patient	O
received	O
two	O
separate	O
oral	O
administrations	I:C0001563
of	O
melatonin	O
10	O
mg	O
.	O

During	O
the	O
study	O
,	O
each	O
patient	O
received	O
two	O
separate	O
oral	B:C0001563
administrations	I:C0001563
of	O
melatonin	O
10	O
mg	O
.	O

Melatonin	B:C0025219
was	O
administered	O
60	O
min	O
before	O
surgery	O
,	O
and	O
at	O
9:00	O
p.m.	O
the	O
evening	O
after	O
surgery	O
.	O

Melatonin	O
was	O
administered	B:C0806914
60	O
min	O
before	O
surgery	O
,	O
and	O
at	O
9:00	O
p.m.	O
the	O
evening	O
after	O
surgery	O
.	O

Melatonin	O
was	O
administered	O
60	O
min	O
before	O
surgery	B:C0543467
,	O
and	O
at	O
9:00	O
p.m.	O
the	O
evening	O
after	O
surgery	O
.	O

The	O
pharmacokinetic	O
variables	O
absorption	O
half	O
-	O
life	O
(	O
t	O
½	O
absorption	O
)	O
,	O
time	O
to	O
maximal	O
plasma	O
concentration	O
(	O
T	O
max	O
)	O
,	O
maximal	O
plasma	O
concentration	O
(	O
C	O
max	O
)	O
,	O
elimination	O
half	O
-	O
life	O
(	O
t	O
½	O
elimination	O
)	O
,	O
and	O
area	O
under	O
the	O
melatonin	O
plasma	O
concentration	O
-	O
time	O
curve	O
from	O
time	O
zero	O
to	O
infinity	O
(	O
AUC	O
∞	O
)	O
were	O
estimated	O
for	O
both	O
study	B:C2603343
phases	O
.	O

C	O
max	O
values	O
were	O
significantly	O
higher	O
during	O
surgery	B:C0543467
[	O
5497.5	O
(	O
2077.1-13,233.8	O
)	O
pg/ml	O
]	O
compared	O
with	O
postoperative	O
values	O
[	O
2340.5	O
(	O
1672.4-8871.4	O
)	O
pg/ml	O
]	O
(	O
p	O
=	O
0.005	O
)	O
.	O

AUC	O
∞	O
did	O
not	O
differ	O
between	O
the	O
study	B:C2603343
phases	O
(	O
p	O
>	O
0.05	O
)	O
.	O

These	O
preliminary	O
results	O
indicate	O
that	O
postoperative	O
melatonin	B:C0025219
dose	O
should	O
be	O
augmented	O
compared	O
with	O
preoperative	O
administration	O
if	O
corresponding	O
melatonin	O
plasma	O
levels	O
are	O
intended	O
.	O

These	O
preliminary	O
results	O
indicate	O
that	O
postoperative	O
melatonin	O
dose	O
should	O
be	O
augmented	O
compared	O
with	O
preoperative	O
administration	B:C3469597
if	O
corresponding	O
melatonin	O
plasma	O
levels	O
are	O
intended	O
.	O

These	O
preliminary	O
results	O
indicate	O
that	O
postoperative	O
melatonin	O
dose	O
should	O
be	O
augmented	O
compared	O
with	O
preoperative	O
administration	O
if	O
corresponding	O
melatonin	B:C0025219
plasma	O
levels	O
are	O
intended	O
.	O

These	O
preliminary	O
results	O
indicate	O
that	O
postoperative	O
melatonin	O
dose	O
should	O
be	O
augmented	O
compared	O
with	O
preoperative	O
administration	O
if	O
corresponding	O
melatonin	O
plasma	B:C0032105
levels	O
are	O
intended	O
.	O

Furthermore	O
,	O
postoperative	O
administration	B:C3469597
times	O
should	O
be	O
advanced	O
compared	O
with	O
preoperative	O
administration	O
.	O

Furthermore	O
,	O
postoperative	O
administration	O
times	O
should	O
be	O
advanced	O
compared	O
with	O
preoperative	O
administration	B:C3469597
.	O

